ClinicalTrials.gg
TerminatedNCT05605119SURYA-1Updated Apr 17, 2026

First in Human, Dose Escalation, Dose Expansion Study of AUR105

A Phase 1 interventional study of AUR105 in Solid Tumor, Adult, Non-hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by Aurigene Discovery Technologies Limited. Terminated at 9 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Aurigene Discovery Technologies Limited (part of Dr. Reddy's Laboratories Limited) · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Patient recruitment problems.

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Lymphoma, Non-Hodgkin with a site in India — 2 open to participants now, 3 under way, 1 of them phase 3. Lymphoma, Non-Hodgkin · India.

Enrollment
14th of 15
17 · median 256
Started
2022
with 1 other
Phase 1
4 of 16
1 open now
Registered
13th of 16
by date
Lead sponsor
4 of 16
Aurigene Discovery Technologies Limited

Among the 16 studies in Lymphoma, Non-Hodgkin with a site in India, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 1, and was the 13th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 16 studies in Lymphoma, Non-Hodgkin with a site in India are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Lymphoma, Non-Hodgkin with a site in India, or all of them as a file.
02

Study summary

This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies.

The study will have two parts: a Dose Escalation Part and Dose Expansion Part.

Read the detailed description

This is a Phase I, Open label First in Human Study in adult patients with relapsed advanced malignancies.

The study will have two parts. Dose escalation part and Dose expansion part

03

Conditions studied

  • Solid Tumor, Adult
  • Non-hodgkin Lymphoma
  • Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ≥ 18 years of age
  • (ECOG) Performance status of 0 or 1
  • Acceptable bone marrow and organ function at screening as described below:

≥ 1500/μL (without WBC growth factor support) count ≥ 100,000/μL without transfusion support (Patients with lymphoma are allowed with Platelet count ≥ 75,000 / μL) ≥ 9 g/dL (Transfusion is allowed to achieve this Hb) Total ≤ 1.5 x ; (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin ≤ 2.5 x ULN) (SGOT) ≤ 3 x ULN (≤ 5 × ULN if known liver ) ALT (SGPT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases) (CrCl) ≥ 60 mL/min (either measured or estimated by the Cockcroft-Gault formula). (Cockcroft-Gault formula for estimated creatinine clearance [eCrCl]: eCrCl = [140- Age] × Weight [kg] × [0.85 if Female] / [72 × serum creatinine (mg/dL)]).

  • Ability to swallow and retain oral medications
  • Histo-pathological diagnosis of a solid tumor, Non-Hodgkin lymphoma or Hodgkin Lymphoma
  • Evidence of per , v1.1 for solid tumors (Eisenhauer et al. 2009) and per Lugano Criteria for Lymphoma (Cheson et al. 2014).
  • Standard curative measures do not exist, and patient must have exhausted all effective therapies, available locally.

    1. At a minimum, solid tumor patients must have received at least two in the metastatic incurable settings(these two lines must be in the metastatic setting and not in the earlier stage of cancer).
    2. At a minimum, lymphoma patients must have received at least 2 prior lines of systemic therapies. These systemic therapies could be either in the stage II, III or IV.

Exclusion criteria

Exclusion Criteria:

  • Systemic anti-cancer therapy, such as chemotherapy, or biological therapy, immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from the Cycle 1 Day 1 of the study.
  • Presence of an acute or chronic toxicity resulting from prior anticancer treatment, with the exception of alopecia or nail changes, that has not resolved to Grade ≤ 1, as determined by v 5.0
  • Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed and no restrictions during the screening period or during the trial)
  • Use of any agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1
  • Use of moderate / strong inhibitors/inducers or moderate / strong P-gp inhibitor/inducers within 2 weeks or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1 (The list of these medications is provided in the first four rows of Table 5)
  • Known symptomatic or untreated or recently treated (≤ 6 months of screening) central nervous system (CNS) or CNS lymphoma. Patients with previously treated (> 6 months of screening) or CNS lymphoma and are now stable and asymptomatic, from CNS perspective, are allowed
  • Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia)
  • Patients with leukemia or myelodysplastic syndrome or multiple myeloma
  • Active infection requiring systemic therapy.
  • 10. Prophylactic use of antibiotics is allowed.
  • Any infection detected during screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed.
  • Known to be (HIV) positive or have an acquired immunodeficiency syndrome-related illnessKnown active or chronic (HBsAg +ve) or infection (HCV antibody +ve)
  • The patient who is expected to require any other form of antineoplastic therapy or targeted therapy while on study.
  • Uncontrolled congestive heart failure ( [NYHA] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or , or pulmonary embolism within 3 months prior to Cycle 1 Day 1
  • Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in past 3 months, before Cycle 1 Day 1
  • (Bazzett) interval >450 ms for male patients or >460 ms for female patients on at screening and/or at Cycle 1 Day 1 predose.
  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence
  • Current swab-positive or suspected (under investigation) Covid19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of person(s) with confirmed Covid-19 infection, at screening or Day 1 of Cycle 1
  • History of another primary within 5 years prior to starting study drug, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study.
  • Positive pregnancy test for women of (WOCBP) at the screening or enrolment visit
  • Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable methods (hormonal contraceptive, IUD, or any double combination of male or female condom, spermicidal gel, diaphragm, sponge, cervical cap)
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    AUR105 50mg to 750mg

    Currently planned dose levels in Part 1 are 50mg, 100mg, 200mg, 300mg, 450mg, 600mg and 740mg once daily

    Drug: AUR105

Interventions

  • DrugAUR105

    Once daily

06

What researchers measure

Primary outcomes

  1. Primary Endpoints

    First cycle DLT

    Time frame: 28 Days

  2. Primary Endpoints

    PK parameters - Cmax

    Time frame: Day 16

  3. Primary Endpoints

    PK parameters- AUC

    Time frame: Day 16

  4. Primary Endpoints

    PK parameters- Tmax

    Time frame: Day 16

  5. Primary Endpoints

    Recommended Phase 2 Dose determination

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Exploratory Endpoints:

    PD biomarkers (SDMA)

    Time frame: Day 15

  2. Exploratory Endpoints:

    Efficacy assessments overall response rate

    Time frame: Through study completion, an average of 1 year

  3. Exploratory Endpoints:

    Efficacy assessments- duration of response

    Time frame: Through study completion, an average of 1 year

  4. Exploratory Endpoints:

    Efficacy assessments- PFS

    Time frame: Through study completion, an average of 1 year

  5. Exploratory Endpoints:

    Change in Tumor Specific Markers - CA-125 in ovarian cancer

    Time frame: Through study completion, an average of 1 year

  6. Exploratory Endpoints:

    Change in Tumor Specific Markers - PSA in Castrate Resistant Prostate Cancer

    Time frame: Through study completion, an average of 1 year

  7. Exploratory Endpoints:

    Change in Tumor Specific Markers - CEA in colorectal cancer

    Time frame: Through study completion, an average of 1 year

07

Study locations

9 sites
  • HCG City Cancer Center
    Vijayawada, Andhra Pradesh 520002, India
  • Omega Hospitals
    Visakhapatnam, Andhra Pradesh 530040, India
  • IMS&SUM Hospital
    Bhubaneswar, Bhubaneswar 751003, India
  • Kailash Cancer Hospital and Research Centre
    Vadodara, Gujarat 391760, India
  • Krupamayi Hospital
    Aurangabad, Maharashtra 431001, India
  • Moraya Multi-Speciality Hospital
    Pune, Maharasthra 411033, India
  • ALL India Institute of medical Scieneces
    New Delhi, New Delhi 110029, India
  • Sparsh Hospital and Critical Care
    Bhubaneswar, Odisha 751007, India
  • All India Institute of Medical Sciences
    Bhubaneswar, Odisha 751019, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Mar 2024, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2022
First posted
Nov 4, 2022
StartActual
Nov 30, 2022
Primary completionActual
Mar 1, 2024
CompletionActual
Mar 1, 2024
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05605119
Responsible party
Sponsor
First posted
Nov 4, 2022
Start date
Nov 30, 2022
Primary completion
Mar 1, 2024
Completion
Mar 1, 2024
Last update
Apr 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion